Skip to main content
. 2001 Apr;51(4):329–334. doi: 10.1046/j.1365-2125.2001.01361.x

Table 2.

The effect of allopurinol and placebo on the mean plasma uric acid, indices of heart rate variability, mean heart rate and arrhythmias in the study groups and on heart rate variability in sub-groups of patients with significantly low baseline HRV (i), high plasma uric acid baseline (ii) or both (iii).

Parameters Baseline (mean ± s.d.) Placebo (mean ± s.d.) Allopurinol (mean ± s.d.) P-value placebo vs. allopurinol 95% CI placebo vs. allopurinol
Groups
SDNN (ms) 139 ± 56 137 ± 49 131 ± 52 0.18 (− 3.4, 16.5)
SDANN (ms) 118 ± 44 110 ± 37 113 ± 38 0.68 (− 17, 11)
SDNNi 68 ± 56 62 ± 42 66 ± 51 0.76 (− 12, 16)
RMSSD (ms) 45 ± 36 46 ± 33 45 ± 33 0.68 (− 5.6, 3.7)
Triangular index 35 ± 16 34 ± 13 31 ± 14 0.5 (− 5.2, 0.8)
Log ventricular ectopies 5.9 ± 1.7 5.7 ± 1.9 5.8 ± 1.8 0.7 (− 0.5, 0.3)
Mean heart rate (beats min−1) 68 ± 12 69 ± 10 70 ± 13 0.5 (− 2, 3.8)
Plasma uric acid (mmol l−1) 0.52 ± 0.08 0.52 ± 0.08 0.34 ± 0.05 <0.0001 (0.11, 0.22)
Subgroups
(i)
SDNNi (ms) 32 ± 12 34 ± 10 34 ± 8 0.4 (− 7.6, 3.7)
RMSSD (ms) 26 ± 15 27 ± 13 30 ± 14 0.2 (− 12, 3.4)
Triangular index 20 ± 8 20 ± 9 20 ± 8 1 (− 5.1, 4.8)
(ii)
SDNNi (ms) 67 ± 55 65 ± 53 66 ± 51 0.87 (− 5.01, 5.7)
RMSSD (ms) 47 ± 38 49 ± 37 50 ± 36 0.27 (− 9.3, 2.8)
Triangular index 35 ± 17 34 ± 16 32 ± 15 0.08 (− 0.4, 6.4)
(iii)
SDNNi (ms) 32 ± 12 33 ± 10 34 ± 8 0.4 (− 7.6, 3.7)
RMSSD (ms) 22 ± 10 25 ± 9 27 ± 12 0.2 (− 15, 12)
Triangular index 19 ± 9 19 ± 88 20 ± 9 0.8 (− 6.2, 5.5)

HRV, heart rate variability; rMSSD, root-mean-square of the successive normal sinus RR interval difference; SDANN, standard deviation of the averaged normal sinus RR intervals for all 5 min segments; SDNN, standard deviation of all normal sinus RR intervals over 24 h; SDNNi, mean of the standard deviations of all normal sinus RR intervals for all 5 min segments; TI, triangular index; CI, confidence intervals.